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progressive disorder characterized by an increased liver volume
due to many (>20) ﬂuid-ﬁlled cysts of biliary origin. Disease caus-
ing mutations in PRKCSH or SEC63 are found in 25% of the PCLD
patients. Both gene products function in the endoplasmic reticu-
lum, however, the molecular mechanism behind cyst formation
remains to be elucidated. As part of the translocon complex,
SEC63 plays a role in protein import into the ER and is implicated
in the export of unfolded proteins to the cytoplasm during ER-
associated degradation (ERAD). PRKCSH codes for the b-subunit
of glucosidase II (hepatocystin), which cleaves two glucose resi-
dues of Glc3Man9GlcNAc2 N-glycans on proteins. Hepatocystin
is thereby directly involved in the protein folding process by reg-
ulating protein binding to calnexin/calreticulin in the ER. A sepa-
rate group of genetic diseases affecting protein N-glycosylation in
the ER is formed by the congenital disorders of glycosylation
(CDG). In distinct subtypes of this autosomal recessive multisys-
tem disease speciﬁc liver symptoms have been reported that
overlap with PCLD. Recent research revealed novel insights in
PCLD disease pathology such as the absence of hepatocystin from
cyst epithelia indicating a two-hit model for PCLD cystogenesis.
This opens the way to speculate about a recessive mechanism
for PCLD pathophysiology and shared molecular pathways
between CDG and PCLD. In this review we will discuss the clini-
cal-genetic features of PCLD and CDG as well as their biochemical
pathways with the aim to identify novel directions of research
into cystogenesis.
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neutral AB.The identiﬁcation of the genes that underlie congenital disorders
of glycosylation (CDG) has led to tremendous insight into the
physiology of processing and transport of glycoproteins. Often,
these discoveries have had little impact in hepatology as most
CDG are recessive and extremely rare, and present liver symp-
toms as part of a multisystem disease. Indeed, as underlined by
a recent review in this Journal, hepatologists have mainly focused
on disturbed glycosylation of speciﬁc glycoproteins in an effort to
identify biomarkers or explain certain elements of liver pathology
such as liver ﬁbrosis [1]. The recent discovery of genes involved in
glycoprotein processing as the cause of an autosomal dominant
form of polycystic liver disease (PCLD) opens up the possibility
for a comprehensive mapping of the role of protein glycosylation
in liver pathology. The focus of this review will be on PCLD and
we will discuss the role of the SEC63 and PRKCSH gene products
in protein glycosylation. Finally, we will highlight a number of
CDG subtypes in terms of their liver pathology and discuss their
pathology in relation to PCLD.Polycystic liver disease
Clinical presentation
Autosomal dominant polycystic liver disease (PCLD) is a rare pro-
gressive disease characterized by an increased liver volume due
to many (>20) ﬂuid-ﬁlled cysts [2] (Fig. 1). The cells lining the
cysts originate from bile duct epithelial cells which normally
shape the biliary tree [3]. During embryonic development, bile
ducts arise from the ductal plate through growth and apoptosis.
In PCLD, dense complexes of intralobular bile ductules remain
intact and are termed Von Meyenburg complexes [4]. These com-
plexes develop into cysts by disconnecting from the biliary tree.
Subsequent epithelial ﬂuid secretion and growth create the
mature cyst [5,6]. Symptoms arise due to continuous cyst growth
and the corresponding increase in liver volume of PCLD patients
[5,7]. Most patients are diagnosed between 30 and 40 years of
age when they start to suffer from the increased liver volume
and the pressure it exerts on other organs. They can experience10 vol. 52 j 432–440
Fig. 1. Phenotype of PCLD. (A) The bulging abdomen of a severely affected patient. (B and C) Stills from a laparoscopic surgical procedure in an affected patient. In both
stills, the cysts are readily identiﬁable. The right section of the ﬁgure shows representative transversal (D) and coronal (E) sections of a computer tomography. Note that
there are multiple liver cysts but that the kidney is normal.
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breath as a result of reduced lung capacity [5]. Although the cysts
disturb the normal structure and shape of the liver, the liver func-
tions normally in these patients. There is a remarkable difference
in disease severity between man and women. The latter are more
severely affected and have larger liver volumes compared to their
age matched male counterparts. Pregnancies (and oral anticon-
ceptives) seem to further stimulate cyst growth in women [5],
indicating that female sex hormones play a role in cyst
development.
Polycystic livers are also seen in patients with autosomal dom-
inant polycystic kidney disease (ADPKD). ADPKD is caused by
mutations in either the PKD1 or the PKD2 gene and is characterized
by the presence ofmultipleﬂuid-ﬁlled cysts in the kidney [8]. PCLD
is different from ADPKD, since it is not linked to the PKD1 or PKD2
gene and PCLD patients do not develop kidney cysts.
So far, treatment options consist of aspiration sclerotherapy,
in which cyst volume is reduced by aspiration [9]. Other options
include surgical measures aimed to relieve the symptoms by
mechanically reducing the number of cysts or cyst volume
[10,11] as well as liver transplantation [12]. Medical therapeutic
options for PCLD patients are around the corner. A recent ran-
domized, double-blind, placebo-controlled trial of polycystic liver
patients with the somatostatin analogue lanreotide, showed that
this treatment led to a signiﬁcant decrease in polycystic liver vol-
ume by 4.5% [13].
Pathways involved in PCLD
Two genes are associated with PCLD, and heterozygous muta-
tions found in these genes explain about 25% of the cases. Protein
Kinase C Substrate 80K-H (PRKCSH) was identiﬁed in 2003 as the
ﬁrst causative gene for PCLD [14,15], while one year later SEC63
mutations were found in different families [16]. Both genes areJournal of Hepatology 201located in the ER and function in the early secretory route of
the cell. The protein encoded by SEC63 (SEC63) functions in pro-
tein translocation in the ER, while the protein encoded by PRKCSH
(hepatocystin) acts in the protein folding process. Both genes are
ubiquitously expressed in the human body [14–16].
SEC63
In the cell, SEC63 is located in the membrane of the endoplasmic
reticulum (ER) where it is involved in protein transport across the
ER membrane [17]. The main player in ER translocation is the
Sec61 complex, which is also called the translocon. This hetero-
trimeric complex, consisting of Sec61a, Sec61b and Sec61c, forms
a transmembrane channel through which nascent proteins are
translocated into the ER during protein translation (co-transla-
tional) and after being fully synthesized (post-translational).
The translocon requires additional factors like SEC63 to drive
the translocation and the composition of the total complex can
vary (reviewed in [18]). Extensive research in yeast showed that
Sec63p is required for both co-translational and post-transla-
tional translocation (Fig. 2). In the post-translational pathway
the C-terminal domain of Sec63p is important for the formation
and stability of the Sec62p/Sec63p/Sec71p/Sec72p complex that
recruits precursor proteins to the translocon in the absence of
ribosomes [19–22]. The J-domain of Sec63p interacts with the
ER chaperone binding immunoglobulin protein (BiP) located in
the ER and this interaction provides the driving force for protein
translocation [23]. After ATP regulated interaction with the DnaJ
domain of Sec63p, multiple BiP molecules bind the nascent pro-
tein and thereby prevent retrograde movement of the protein
through the translocon [24–26]. The co-translational pathway
also requires functional Sec63p, but here the ribosomes provide
the nascent proteins and the C-terminal domain required for
the stabilization of Sec62p in the post-translational pathway is0 vol. 52 j 432–440 433
Fig. 2. Functions of SEC63. In yeast, Sec63p is involved in the structure of the translocon complex and plays an active role in protein translocation through interaction with
BiP. In this way, Sec63p is required for co-translational (1) and post-translational (2) protein translocation across the ER membrane. Retrograde protein transport of
misfolded proteins from the ER back to the cytoplasm also requires Sec63p (3). Furthermore, as BiP seals the translocon when it is not in use, a putative role of Sec63p is to
facilitate this interaction and gate the translocon (4).
Reviewnot imperative in the co-translational pathway [19,27]. Transport
of proteins from the ER back to the cytoplasm occurs during ER-
associated degradation (ERAD), where ER proteins prone for deg-
radation are transported through the translocon back to the cyto-
plasm for degradation by the proteasome [28]. In yeast, Sec63p
and BiP co-precipitate with ER-associated proteasomes and
mutations in Sec63p or BiP affect degradation of unfolded pro-
teins in the ER [29,30]. BiP recognizes hydrophobic regions of
misfolded or partially assembled proteins and promotes ER
retention and protein folding [31]. Furthermore, mutations in
yeast SEC63 lead to a signiﬁcant reduction in the export of mis-
folded glycoproteins from the ER [32]. Collectively, these data
show the involvement of Sec63p in protein translocation into
and out of the ER (Fig. 2). In addition, Sec63p is proposed to be
involved in gating the translocon by interacting with BiP, which
blocks ion transport through the translocon when the channel
is not in use for protein translocation [33,34].
In mammalian cells, the role of SEC63 is still unclear. It has
been shown that SEC63 binds the ribosome free SEC61 complex
(post-translational and ERAD), but is not associated with the
co-translational ribosome–SEC61 complex [35]. Subsequent
investigations showed that only a fraction of the available
SEC63 was bound to SEC61 [35,36], which might implicate addi-
tional and still to be identiﬁed molecular functions for SEC63 in
mammalian cells. The role of mammalian SEC63 in ERAD remains
unclear because the protein complex facilitating retrograde pro-
tein transport in mammalian cells has not yet been identiﬁed.434 Journal of Hepatology 201Hepatocystin
Hepatocystin function has been associated with several subcellu-
lar processes. In COS-7 cells and in hippocampal neurons, hepat-
ocystin was shown to interact with and regulate the activity of
inositol 1,4,5-trisphosphate receptors (IP3Rs), which regulate
Ca2+ release from the ER [37]. In the plasma membrane of numer-
ous human cell types (including mononuclear, endothelial, renal,
brain neuronal and glial cells), hepatocystin was suggested to act
as an advanced glycation end product (AGE) receptor mediating
cell activation, chemotaxis and cell secretion [38]. In HEK293
cells, plasma membrane hepatocystin was found to interact with
the epithelial Ca2+ channel TRPV5 [39]. Furthermore, hepatocy-
stin and its bovine orthologue VASAP-60, have been implicated
in intracellular vesicle transport in CHO and bovine luteal cells,
respectively [40,41]. Recently, hepatocystin was also found to
be involved in ﬁbroblast growth factor (FGF) signaling in human
breast cancer cells and rat myoblast cells [42,43]. Taken together,
hepatocystin has been implicated in a multitude of functions in
several subcellular locations.
Hepatocystin is predominantly localized to the ER, where it
functions as the b-subunit of the ER enzyme alpha glucosidase
II [44]. This enzyme consists of two subunits, a and b, which
strongly interact to form a heterodimeric protein complex [45].
Both subunits play an important role in the function of the com-
plex [46], which is involved in glycoprotein processing (Fig. 3). In
the ER, oligosaccharide structures (glycans) are attached to nas-0 vol. 52 j 432–440
Fig. 3. Glycan modiﬁcations and protein quality control in the ER including involved genes and CDG subtypes. Formation of the glycan involves several enzymatic
steps. After completion (1) the glycan is transferred by oligosaccharyltransferase (OTase) to nascent proteins entering the ER through the translocon. The ﬁrst glucose
residue is cleaved by glucosidase I (Glc-I) (2), the second glucose is cleaved by glucosidase II (Glc-II) (3). The resulting structure with one remaining glucose residue
interacts with the ER folding machinery. Cleavage of the last glucose residue by glucosidase II releases the protein from the ER chaperones and makes the protein available
for transport to the Golgi (4). Partly unfolded proteins cleaved by glucosidase II are reglucosylated by UDP-glucose glycoprotein glucosyltransferase (UGGT) to restore the
interaction with the folding machinery (5). Proteins that remain unfolded are ultimately transported back to the cytoplasm and degraded by the proteasome (6). In orange
the CDG subtype abbreviations and involved PCLD genes are shown.
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cent glycoproteins to assist in their solubility, folding, and quality
control (as reviewed by [47]). In brief, the glycans (Glc3Man9Glc-
NAc2) are synthesized on the lipid dolichol, anchored in the ER
membrane, and are then transferred en bloc to nascent proteins
emerging into the ER lumen during co- or post-translational
translocation. After attachment, the glycan is modiﬁed by gluco-
sidase I and glucosidase II, which cleave speciﬁc glucose residues
from the glycan. Nascent proteins depend on this glucose cleav-
age for their interaction with the folding chaperones in the ER.
Immediately after glycan attachment, the ﬁrst glucose is cleaved
by glucosidase I, after which the remaining two glucoses are
cleaved by the glucosidase II complex in a more controlled man-
ner [48]. After the ﬁrst two cleavages, a Glc1Man9GlcNAc2 struc-
ture remains which is bound by the luminal ER chaperones
calnexin and calreticulin. ERp57 associates with calnexin/calreti-
culin and mediates disulﬁde bond formation and folding of the
nascent glycoprotein. Cleavage of the ﬁnal glucose residue by
the glucosidase II complex subsequently releases the nascent
protein from calnexin/calreticulin [49]. Properly folded proteins
are then transferred to the Golgi for further post-translational
modiﬁcation. When the protein is not folded properly, it is reglu-
cosylated by UDP-glucose glycoprotein glucosyltransferase in
order to enter the cycle again. Finally, misfolded proteins enter
ERAD and are transported back to the cytoplasm for degradation.
The function of glucosidase II depends on both subunits. Even
though the a-subunit (GANAB) holds the enzymatic activity in
the complex, hepatocystin is essential for the activation and
proper function of the enzyme. Yeast cell mutants, deﬁcient for
either the a-subunit or hepatocystin were both devoid of full glu-
cosidase II activity, but viable under non-stress conditions. The
hepatocystin mutants did show products of the ﬁrst glucosidase
II cleavage but not of the second cleavage, indicating that hepat-
ocystin is essential for the cleavage of the glucose–mannose link-
age [50,51]. In mammalian cells it was shown that hepatocystin
is necessary for the solubility, retainment in the ER and activation
of the a-subunit of human glucosidase [52] and that transfection
of the a-subunit without its b-subunit resulted in an inactive pro-
tein [53]. The b-subunit contains a speciﬁc HDEL ER retention sig-
nal and retains the glucosidase II enzyme complex in the ER
[45,52,54]. Mutation of this HDEL sequence leads to secretion
of the a-subunit [52]. In addition, the number of glycans present
on a protein was also shown to affect the kinetics of glucosidase
II, two glycans are more efﬁciently cleaved compared to one [48].
The glucosidase II complex has one active site but two binding
afﬁnities and it is proposed that hepatocystin can bind the man-
nose branch of a glycan with its mannose-6-phosphate receptor
domain causing a conformational change allowing effective
cleavage of the last glucose [52,53,55].
The glycoprotein quality control system depends on proper
functioning of the glucosidase II complex. Incomplete glucose
cleavage results in reduced rates of protein folding, accelerated
protein degradation, reduced expression of cell-surface proteins
and defects in protein secretion [50,56–58]. Some proteins
depend heavily on the folding machinery of the ER and cannot
obtain their native conformation without glucosidase II cleavage
and subsequent interaction with the ER chaperones [59,60]. In
contrast, other proteins are still able to fold and reach the Golgi
in the absence of glucosidase II. Additionally, alternative isoforms
are described for the a-subunit and hepatocystin with speciﬁc
afﬁnity for different glycoproteins. For example, only alterna-
tively spliced hepatocystin can associate with CD45 in hemato-436 Journal of Hepatology 201poietic cells [61]. This substrate speciﬁcity is interesting and
alternative splicing in different cell types may explain the liver
speciﬁc phenotype of PCLD.Congenital disorders of glycosylation
N-glycosylation pathway in the ER
Protein N-linked glycosylation is an important process in the
secretory pathway of the cell (Fig. 3). In the ER, it overlaps with
the process of protein translocation and folding, starting with
the transfer of the Glc3Man9GlcNAc2 oligosaccharide by oli-
gosaccharyltransferase (OTase) followed by the action of ER man-
nosidase I and subsequent transport to the Golgi apparatus [47].
Formation of the oligosaccharide is initiated on the cytoplasmic
side of the ER membrane by addition of glucosamine to doli-
chol-phosphate. After extension to a dolichol linked Man5Glc-
NAc2 glycan, ﬂipping of the glycan into the ER lumen is
mediated by the ﬂippase RFT1. Further extension occurs in a
highly ordered manner by ER mannosyltransferases with differ-
ent substrate speciﬁcity. Subsequent action of the ALG6, ALG8
and ALG10 glucosyltransferases leads to the ﬁnal dolichol linked
glycan Glc3Man9GlcNAc2, which is the recognized substrate for
OTase. This oligosaccharyltransferase complex, composed of
eight subunits and associated with the SEC61 complex in the
ER membrane [62], recognizes the terminal glucose residues
and transfers the glycan onto nascent polypeptide chains con-
taining the Asn-Xaa-Ser/Thr amino acid consensus sequence. Fol-
lowing glucosidase I and II action, the glycoprotein enters the
folding machinery as described under 1.2 (Fig. 3). After proper
folding and removal of a terminal mannose residue, the glycopro-
tein ﬁnds its way towards the Golgi, where processing of the gly-
cans occurs.
Genetic defects in protein N-linked glycosylation occur in a
group of autosomal recessive diseases, termed CDG. Two types
can be distinguished based on the function of the gene involved.
In CDG type I, the assembly of the dolichol linked Glc3Man9Glc-
NAc2 oligosaccharide is affected or its transfer to nascent poly-
peptides by OTase. In CDG type II processing of protein linked
glycans either in the ER or Golgi is affected.
Since many different enzymes are required for a proper glyco-
sylation of proteins, CDG’s are genetically heterogeneous result-
ing in many different clinical subtypes (Table 1). Although each
individual genetic defect will lead to a similar underglycosylation
of glycoproteins in CDG type I, speciﬁc clinical features seem to
be present in distinct subtypes.
Presence of liver disease in CDG
Most CDG are multisystem diseases with a high mortality, char-
acterized by neurological symptoms, gastro-intestinal problems,
coagulopathy and endocrine and dysmorphic abnormalities. In
most patients liver symptoms are involved. In some CDG sub-
types, liver problems as hepatomegaly or hepatic ﬁbrosis are
present as key symptoms. Since hepatocystin and SEC63 are both
expressed in the ER, we will focus on the liver phenotype of ER-
localized CDG genes (see also Fig. 3 and Table 1).
Startingwith theﬁrst defect in the lumenof theER,mutations in
ALG3 affectMan5GlcNAc2-PP-Dol extension in CDG-Id. Diminished
liver function has been reported in two patients and two siblings0 vol. 52 j 432–440
Table 1. Genes and reported liver symptoms in CDG. This table describes the CDG subtype (ﬁrst column) with the affected gene (second column) and the accumulating
substrate of the affected enzyme (third column). The liver symptoms (fourth column) include positive ﬁndings extracted from available case reports (references in ﬁfth
column).
Gene Liver symptomsOligosaccharide ReferenceCDG
RFT1
ALG3
ALG9
ALG12
ALG6
ALG8
GLS1
unknown
Man5GlcNAc2
Man
5
GlcNAc
2
Man
6
GlcNAc
2
Man
7
GlcNAc
2
Man
8
GlcNAc
2
Glc
1
Man
9
GlcNAc
2
Glc
2
Man
9
GlcNAc
2
unknown
hepatomegaly
hepatomegaly
hepatomegaly
bile duct malformations 
diminished liver function
fibrosis 
bile lakes
hepatomegaly
abnormal hepatic lysosomal inclusions
hepatomegaly
multiple cystic bile ducts
dilated bile ducts 
elevated liver enzyme activity
cholestasis
hepatomegaly
dilatation and proliferation of bile ducts 
cholangiofibrosis
steatosis
cholestasis
steatosis
fibrosis
abnormal hepatic lysosomal inclusions
elevated liver enzyme activity
In
Id
IL
Ig
Ic
Ih
IIb
x
 
[82]
[63-65]
[66-68]
[69-71]
[72-74]
[75-77]
[78]
[74, 83]
JOURNAL OF HEPATOLOGYwith CDG-Id [63–65]. In one of these patients, hepatomegaly, bile
lakes and liver ﬁbrosis were observed. Histologically, the liver
showedbileductmalformations,whichweredeﬁnedby thepersis-
tence of an excess of embryological bile duct structures in ductal
plate conﬁguration [63]. Mutations in the next gene, ALG9, lead
to accumulation of Man6GlcNAc2-PP-Dol causing CDG-IL. In three
CDG-IL patients, hepatomegaly was observed, while 1 patient also
suffered from enlarged, cystic kidneys [66–68]. No report on liver
biopsy was available. No hepatomegaly was observed in ALG12
deﬁcient CDG-Ig patients, in whichMan7GlcNAc2-PP-Dol accumu-
lates. Some of these patients showed an elevated activity of liver
enzymes [69–71]. In CDG-Ic, Man9GlcNAc2-PP-Dol accumulated
due to an ALG6 defect. CDG-Ic is generally characterized by amore
neurological phenotype with epilepsy as prominent symptom,
whereas liver involvement has been reported, including hepato-
megaly [72,73]. Furthermore, in three CDG-Ic patients, liver biop-
sies revealed abnormal lysosomal inclusions in hepatocytes [74],
but no bile duct abnormalities. CDG-Ih is caused by a defect in
the ﬁrst glucosyltransferase, ALG8, leading to Glc1Man9GlcNAc2-
PP-Dol accumulation. Interestingly, CDG-Ih is characterized by a
severe hepato-intestinal phenotype with elevated liver enzymes
and hepatomegaly [75–77]. Liver biopsy was performed in one
patient, showing multiple, cystic, dilated intra- and extrahepatic
bile ducts. This patient also developed cholestasis and diffuse renal
microcysts [77]. The ﬁrst defect after transfer of the dolichol linked
glycan to the nascent protein, CDG-IIb, is caused by deﬁcient activ-
ity of glucosidase I (GLS1) leading to protein linked Glc3Man9Glc-Journal of Hepatology 201NAc2 structures. In one neonate patient, progressive
hepatomegaly was observed and the patient died at 74 days. Post
mortem lightmicroscopyof the liver revealeddilatationandprolif-
eration of the bile ducts. Furthermore, the liver displayed progres-
sive cholangioﬁbrosis, steatosis, cholestasis and the appearance of
bile thrombi in hepatocytes and bile ducts [78]. Finally dilated bile
canaliculi have also been observed in untyped CDG patients [75].Discussion
Glycosylation is an important cellular process and defects in gly-
cosylation can lead to a large variety of cellular defects and
human disorders. PRKCSH, one of the two genes associated with
PCLD, is directly involved in the N-glycosylation machinery in
the ER and plays a role in protein folding. Most CDG are recessive
diseases where patients carry mutations in both alleles of the
affected gene. In contrast, PCLD is an autosomal dominant disease
with a heterozygous germ line mutation, affecting only one allele
of the affected gene. It was shown that in patients with a hetero-
zygous PRKCSH mutation hepatocystin is normally expressed in
most parts of the liver but hepatocystin was absent from bile duct
cells lining the cysts [44]. This suggests that the wild-type
PRKCSH allele is lost from the cyst epithelium through a somatic
second hit mutation (Fig. 4). Examples of a cellular recessive
mechanism in related dominant diseases are hereditary multiple0 vol. 52 j 432–440 437
Fig. 4. Loss of wild-type allele through second hit mutation. Somatic mutations can occur sporadically throughout life and affect single cells. As most genes are presented
by two functional alleles, a somatic mutation in one allele will often not affect the expression of this gene in the cell. Total gene loss only occurs if in the same cell both
alleles would acquire a mutation (A). However, if an inherited mutation (germ line mutation) inactivates one allele, all the cells in the body are left with only one functional
allele of that speciﬁc gene. A single somatic mutation affecting the remaining allele can cause loss of gene expression in these cells (B). As a result, the chance of total gene
loss is much higher in someone with a germline mutation. How the gene loss will affect the cell depends on the gene and the type of cell involved. In the case of PCLD loss of
PRKCSH or SEC63 from a bile duct cell appears to result in the formation of a liver cyst.
Reviewexostoses [79] and ADPKD [80]. Complete loss of PRKCSH from
the cyst epithelium is expected to affect the function of glucosi-
dase II and as a consequence glycosylation and protein folding
in these cells. This seems to be conﬁrmed by the ﬁnding that in
cyst epithelial cells, speciﬁc membrane proteins are retained in
the ER whereas these proteins are normally distributed in hepat-
ocystin expressing biliary cells [56].
PCLD can also be caused by mutations in SEC63, a gene which
is thought to be involved in protein transport into and out of the
ER. Mutations in SEC63 or PRKCSH result in the same disease
which could indicate that the genes are functionally related.
Because in a large percentage of the patients no mutation in
PRKCSH or SEC63 can be identiﬁed, it is likely there is at least
one more (yet unknown) gene involved in the development of
PCLD [81]. Identiﬁcation of this gene may provide the missing
link between the function of SEC63 and hepatocystin. Although
the number of CDG patients per subtype is limited, as is the num-
ber of liver biopsies performed, the few available reports clearly
show an overlap of speciﬁc liver features with PCLD. The liver
biopsies in CDG show dilated bile ducts (CDG-Ib, CDG-Id, CDG-
Ih and CDG-IIb) and liver cysts (CDG-Ih). CDG is recognized early
in life during childhood, whereas PCLD diagnosis is made
between 30 and 40 years. Thus, it seems that development of
liver cysts is much faster in CDG compared to PCLD, where liver
cysts are not detected before 30 years of age. An explanation for
this observation may be that in the CDG patients the gene is lost438 Journal of Hepatology 201in all cells whereas in PCLD only some cells lose the gene through
a second hit mutation.
The biochemical defect of at least two of these subtypes (CDG-
Ih and CDG-IIb) shows considerable overlap with the protein
translocation and folding process in PCLD (Fig. 3). The dolichol
linked glycan that accumulates in CDG-Ih (Glc1Man9GlcNAc2) is
similar to the protein linked glycan in PRKCSH deﬁcient cells,
assuming the second hit model is valid. It has been shown that
incomplete glycans can be transferred from dolichol to proteins,
but at reduced efﬁciency compared to the fully synthesized gly-
cans, and that the abnormal glycan can then affect the folding
and degradation of the protein in the ER [68]. In CDG-Ih cells
the Glc1Man9GlcNAc2 structure may be transferred in small
amounts from dolichol to proteins in the absence of fully synthe-
sized Glc3Man9GlcNAc2, thereby resembling protein glycosyla-
tion in PRKCSH deﬁcient cells. Likewise, defective glucosidase I
in CDG-IIb might interfere in the same biochemical process, e.g.
protein folding or ERAD.Concluding remarks and future perspectives
Much has been learned about PCLD over the last few years, but
still many issues are unclear. By comparing PCLD with CDG we
hope to open a whole new discussion in the pathogenesis of PCLD0 vol. 52 j 432–440
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and gain insight in the underlying molecular mechanisms as well
as to obtain possibilities for future treatments. Future studies
should ﬁrst conﬁrm the two-hit model. Subsequently, it will be
important to investigate the cell type speciﬁc effects of hepatocy-
stin and SEC63 and determine how their absence relates to pos-
sible glycan and protein accumulations. These studies could
also lead to the identiﬁcation of other genes involved in PCLD
pathogenesis, thereby facilitating mutation analysis and screen-
ing in affected families.
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